PubMed Health⌕ Search

Biomedical subjects

S F Kemp

Publications and source records attributed to S F Kemp.

56 records · Page 4Linked to original sources

Assessment of a new blood glucose strip: comparison of Visidex, Visidex II, and Chemstrip bG with Glucose Analyzer determination of blood glucose.

Chemical test strips for estimating blood glucose are reliable, rapid, and convenient when properly used. Ames (Miles Laboratories, Elkhart, Indiana) has recently introduced a new product, Visidex II, which does not require water for development. This study compares the Visidex II with its predecessor Visidex, an established test strip, the Bio-Dynamics Chemstrip bG (Boehringer-Mannheim, Indianapolis, Indiana), and plasma glucose as measured by standard laboratory methods. Determination of blood glucose by visual inspection by all chemical test strips gave an estimation of true plasma glucose, and was reliable in predicting those values that were hypo- and hyperglycemic, although Chemstrip bG tended to underestimate in the hypo- and euglycemic ranges. Visidex II is more convenient to use than Visidex and is equally reliable in estimating true plasma glucose. In addition, strips from 20 patient samples were read daily for 7 days. Reacted Chemstrip bG test strips began to deteriorate within 24 h, and showed a 27% decline in estimations by day 3. Reacted Visidex II strips were stable for 1 day, but then rapidly declined to 50% of the original estimation by day 4.

Blood Glucose↗

Effective use of magnetic resonance imaging in the assessment of children with possible growth hormone deficiency.

OBJECTIVE: To present our experience with diagnosis of growth hormone (GH) deficiency in children and to determine which patients are most likely to benefit from magnetic resonance imaging (MRI). METHODS: We retrospectively reviewed medical records of pediatric patients who underwent assessment for possible GH deficiency during a 6-year period and correlated clinical variables, stimulated GH responses, and MRI findings. RESULTS: Of 100 children who failed outpatient GH screening tests, 14 were classified as at risk for hypothalamic pituitary defects, and 86 were considered not at risk, having short stature only. Patients were further stratified by age, sex, growth variables, maximal GH response to provocative testing, and MRI findings. A significant relationship existed between the presence of risk factors, maximal GH of <5 mg/L, and sellar defects. With no risk factors, MRI scans showed normal findings in 15 of 17 patients with maximal GH of <5 mg/L, in 33 of 34 patients with GH between 5 and 10 mg/L, and in all 35 patients with GH of >10 mg/L. Abnormal MRI findings included posterior pituitary ectopy, decreased pituitary size, absent midline central nervous system structures, enlarged infundibulum, and hamartoma. In one child with a 4-year history of growth failure and a maximal GH of 3.5 mg/L, craniopharyngioma was diagnosed. CONCLUSION: MRI scans should be obtained in any child with multiple pituitary hormone deficiencies, hypoglycemia, ophthalmologic anomalies, low-stimulated GH, or acquired growth failure. Otherwise asymptomatic children with growth delay and maximal GH of >10 mg/L do not need routine MRI screening. Such a strategy could result in substantial cost savings.

Journal Article↗